查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970813

癌症干细胞市场－全球产业规模、份额、趋势、机会与预测：按作用机制、癌症类型、地区和竞争格局划分，2021-2031年

Cancer Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Mode Of Action (Targeted Cancerous Stem Cells, Stem Cell Usage Against Cancer), By Cancer Forms, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球癌症干细胞市场预计将从 2025 年的 37.9 亿美元成长到 2031 年的 61.3 亿美元，复合年增长率为 8.34%。

癌症干细胞是一类具有自我更新和分化能力的特殊癌细胞亚群，是肿瘤发生和转移的主要驱动因素。该市场的成长主要受全球恶性肿瘤发生率上升以及对有效应对肿瘤復发治疗方法的迫切需求所驱动。此外，肿瘤学研发资金的增加也加速了专门针对这些顽固细胞群的新型药物的研发。

市场概览
预测期 2027-2031
市场规模：2025年 37.9亿美元
市场规模：2031年 61.3亿美元
复合年增长率：2026-2031年 8.34%
成长最快的细分市场 胸部
最大的市场 北美洲

儘管取得了这些进展，但市场发展仍面临许多重大障碍，特别是临床试验的高昂成本以及分离特定生物标记的技术难题。然而，日益加重的疾病负担持续推动先进治疗方法的需求。美国癌症协会预测，到2024年，光是美国就将新增约200万例癌症病例。如此高的发生率强烈表明，亟需有效的癌症干细胞靶向策略来克服治疗抗药性带来的挑战，并改善患者的预后。

市场驱动因素

全球癌症发生率和盛行率的不断上升是癌症干细胞市场成长的主要驱动因素，也因此迫切需要先进的治疗性介入。由于传统治疗方法往往无法根除休眠的干细胞亚群，恶性肿瘤负担的加重与预防转移和復发的治疗方法需求的日益增长直接相关。大量患者需要有效的长期护理，凸显了这种紧迫性。根据世界卫生组织（世卫组织）2024年2月发布的《全球癌症负担》报告，2022年全球新增癌症病例估计为2,000万例。展望未来，美国癌症协会预测，到2050年，全球癌症病例将增加至3,500万例，这意味着对创新型干细胞标靶技术的需求将持续成长。

同时，公共和私人研发投资的激增正在加速干细胞生物学向临床应用的转化。分离和鑑定癌症干细胞的复杂性要求对先进的基因组分析和药物筛检平台投入大量资金。资金的增加将使製药公司和学术机构能够克服靶向这些顽强细胞的技术障碍。这种资金投入已在政府的主要预算拨款中充分体现。例如，美国国家癌症研究所（NCI）将在2024年获得约72.2亿美元的拨款，用于支持广泛的肿瘤学研究倡议，从而创造一个有利于癌症干细胞疗法和精准医疗发展的环境。

市场挑战

临床试验的巨额成本是全球癌症干细胞市场扩张的主要障碍。开发有效针对癌症干细胞的疗法需要复杂且长期的研究设计，以检验其不仅能缩小肿瘤，还能预防肿瘤復发和转移。这个漫长的过程需要巨额资金，显着增加了生物製药开发公司的资本风险。因此，这种财务负担阻碍了中小型生物技术公司进入市场，迫使它们优先考虑最具商业性前景的资产，并延缓了创新型癌症干细胞标靶药物的整体开发平臺。

肿瘤学领域的最新数据凸显了这次经济障碍的巨大影响。根据美国临床肿瘤学会（ASCO）估计，到2024年，仅药物一项，进行一项III期癌症临床试验的中位数成本就约为2.449亿美元。如此惊人的成本提高了准入门槛，并直接阻碍了市场扩张，因为它限制了能够成功从临床前研究过渡到监管核准的新治疗方法数量。

市场趋势

从传统的二维培养到3D类器官模型的转变，正在从根本上改变癌症干细胞领域的临床前药物评估。标准的单层培养往往无法复製复杂的肿瘤微环境，而3D繫统则保留了研究干细胞特性和评估抗药性所必需的细胞异质性。这种更真实地模拟人体组织的能力，正推动着对先进建模技术的大量投资，旨在降低临床失败率。例如，在2024年1月的资金筹措公告中，Carcinotech公司宣布已获得420万英镑的资金，用于扩展其3D列印肿瘤建模平台，旨在提高针对复杂癌症结构的资金筹措的准确性，并加快有效治疗方法的上市速度。

同时，人工智慧和深度学习的融合正在简化癌症干细胞的识别和靶向抑制剂的开发。计算平台的速度远超传统方法，能够分析庞大的基因组资料集，进而预测抗药性机制并优化分子结构。这种高效的运作促进了领先的製药公司之间围绕数位生物学的合作，旨在提高研发管线的准确性。例如，礼来公司于2024年1月宣布与Isomorphic Labs建立策略伙伴关係，同意支付4,500万美元的预付款，以获得使用人工智慧技术进行多标靶药物发现的权利。这凸显了製药业对计算创新在应对疑难杂症方面日益增长的依赖。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球癌症干细胞市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 作用机转（标靶癌症干细胞（CSCs），干细胞在癌症治疗的应用）
    • 癌症类型（乳癌、血癌、肺癌）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美癌症干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲癌症干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区癌症干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲癌症干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲癌症干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球癌症干细胞市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Thermo Fisher Scientific, Inc.
  • AbbVie, Inc.
  • Lonza Group Ltd
  • The Menarini Group
  • Miltenyi Biotec BV & Co. KG
  • PromoCell GmbH
  • MacroGenics, Inc.
  • STEMCELL Technologies Canada Inc.
  • Sino Biological, Inc.
  • Lineage Cell Therapeutics, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27649

The Global Cancer Stem Cells Market is projected to expand from a valuation of USD 3.79 Billion in 2025 to USD 6.13 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.34%. Cancer stem cells represent a unique subpopulation of tumor cells endowed with the ability to self-renew and differentiate, acting as the primary drivers behind tumorigenesis and metastasis. The growth of this market is largely fueled by the rising global prevalence of malignancies and the critical need for therapies capable of effectively addressing tumor recurrence. Furthermore, increased financial support for oncology research is accelerating the development of novel agents specifically designed to target these persistent cell populations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.79 Billion
Market Size 2031USD 6.13 Billion
CAGR 2026-20318.34%
Fastest Growing SegmentBreast
Largest MarketNorth America

Despite this progress, market advancement encounters significant hurdles, particularly regarding the substantial costs linked to clinical trials and the technical difficulties involved in isolating specific biomarkers. Nevertheless, the escalating disease burden continues to drive the demand for sophisticated solutions. According to the American Cancer Society, projections for 2024 indicated approximately two million new cancer cases within the United States alone. This high incidence rate underscores the imperative need for effective cancer stem cell targeting strategies to enhance patient outcomes and surmount challenges related to therapeutic resistance.

Market Driver

The escalating global incidence and prevalence of cancer acts as a primary catalyst for the growth of the cancer stem cells market, creating an urgent demand for advanced therapeutic interventions. Since conventional treatments frequently fail to eradicate dormant stem cell subpopulations, the rising burden of malignancy directly correlates with an increased need for therapies designed to prevent metastasis and relapse. This urgency is highlighted by the sheer volume of patients requiring effective long-term care; according to the World Health Organization's 'Global Cancer Burden' report from February 2024, there were an estimated 20 million new cancer cases worldwide in 2022. Looking ahead, the American Cancer Society predicts that global cancer cases will rise to 35 million by 2050, ensuring a sustained trajectory of demand for stem cell-targeted innovations.

Simultaneously, a surge in public and private research and development investments is expediting the translation of stem cell biology into clinical applications. The complexity of isolating and characterizing cancer stem cells requires substantial capital for sophisticated genomic analysis and drug screening platforms. Enhanced funding enables pharmaceutical companies and academic institutions to overcome the technical barriers associated with targeting these resilient cells. This financial commitment is evident in major government allocations; for instance, the National Cancer Institute was allocated a budget of approximately $7.22 billion in 2024 to support broad oncology research initiatives, fostering an environment conducive to breakthroughs in cancer stem cell therapies and precision medicine development.

Market Challenge

The exorbitant costs associated with clinical trials constitute a significant obstacle to the expansion of the Global Cancer Stem Cells Market. Developing therapeutics that effectively target cancer stem cells requires complex and prolonged study designs to validate their ability to prevent tumor recurrence and metastasis, rather than merely reducing tumor mass. These extended timelines necessitate massive financial resources, significantly increasing the capital risk for biopharmaceutical developers. Consequently, this financial burden discourages market entry for smaller biotechnology entities and compels companies to prioritize only the most commercially viable assets, thereby slowing the overall pipeline of innovative stem cell-targeting agents.

The magnitude of this economic barrier is highlighted by recent data from the oncology sector. According to the American Society of Clinical Oncology, the mean drug cost alone for conducting a Phase III cancer clinical trial was estimated to be approximately $244.9 million in 2024. This staggering expense creates a high barrier to entry, directly hampering the market's expansion by limiting the number of novel therapies that can successfully navigate the transition from preclinical research to regulatory approval.

Market Trends

The transition from traditional 2D cultures to 3D organoid models is fundamentally transforming preclinical drug evaluation within the cancer stem cell sector. While standard monolayers often fail to replicate the complex tumor microenvironment, 3D systems preserve the cellular heterogeneity essential for studying stemness and evaluating drug resistance. This capability to better mimic human tissue is driving significant investment into advanced modeling technologies aimed at reducing clinical failure rates. For example, Carcinotech announced in a January 2024 funding release that it secured £4.2 million to expand its 3D-printed tumor model platform, designed to improve the accuracy of testing therapeutics against complex cancer architectures and accelerate the delivery of effective treatments to market.

In parallel, the integration of artificial intelligence and deep learning is streamlining the identification of cancer stem cells and the development of targeted inhibitors. Computational platforms are increasingly capable of analyzing massive genomic datasets to predict resistance mechanisms and optimize molecular structures significantly faster than traditional methods. This operational efficiency has prompted major pharmaceutical alliances centered on digital biology to enhance pipeline precision. Illustrating this trend, Eli Lilly and Company announced a strategic partnership in January 2024, committing an upfront payment of $45 million to Isomorphic Labs to utilize their artificial intelligence technologies for multi-target drug discovery, highlighting the industry's growing reliance on computational innovation to address difficult-to-treat pathologies.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • AbbVie, Inc.
  • Lonza Group Ltd
  • The Menarini Group
  • Miltenyi Biotec B.V. & Co. KG
  • PromoCell GmbH
  • MacroGenics, Inc.
  • STEMCELL Technologies Canada Inc.
  • Sino Biological, Inc.
  • Lineage Cell Therapeutics, Inc.

Report Scope

In this report, the Global Cancer Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Stem Cells Market, By Mode Of Action

  • Targeted Cancerous Stem Cells (CSCs)
  • Stem Cell Usage Against Cancer

Cancer Stem Cells Market, By Cancer Forms

  • Breast
  • Blood
  • Lung

Cancer Stem Cells Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Stem Cells Market.

Available Customizations:

Global Cancer Stem Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Stem Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Mode Of Action (Targeted Cancerous Stem Cells (CSCs), Stem Cell Usage Against Cancer)
    • 5.2.2. By Cancer Forms (Breast, Blood, Lung)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cancer Stem Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Mode Of Action
    • 6.2.2. By Cancer Forms
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cancer Stem Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Mode Of Action
        • 6.3.1.2.2. By Cancer Forms
    • 6.3.2. Canada Cancer Stem Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Mode Of Action
        • 6.3.2.2.2. By Cancer Forms
    • 6.3.3. Mexico Cancer Stem Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Mode Of Action
        • 6.3.3.2.2. By Cancer Forms

7. Europe Cancer Stem Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Mode Of Action
    • 7.2.2. By Cancer Forms
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cancer Stem Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Mode Of Action
        • 7.3.1.2.2. By Cancer Forms
    • 7.3.2. France Cancer Stem Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Mode Of Action
        • 7.3.2.2.2. By Cancer Forms
    • 7.3.3. United Kingdom Cancer Stem Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Mode Of Action
        • 7.3.3.2.2. By Cancer Forms
    • 7.3.4. Italy Cancer Stem Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Mode Of Action
        • 7.3.4.2.2. By Cancer Forms
    • 7.3.5. Spain Cancer Stem Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Mode Of Action
        • 7.3.5.2.2. By Cancer Forms

8. Asia Pacific Cancer Stem Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Mode Of Action
    • 8.2.2. By Cancer Forms
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cancer Stem Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Mode Of Action
        • 8.3.1.2.2. By Cancer Forms
    • 8.3.2. India Cancer Stem Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Mode Of Action
        • 8.3.2.2.2. By Cancer Forms
    • 8.3.3. Japan Cancer Stem Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Mode Of Action
        • 8.3.3.2.2. By Cancer Forms
    • 8.3.4. South Korea Cancer Stem Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Mode Of Action
        • 8.3.4.2.2. By Cancer Forms
    • 8.3.5. Australia Cancer Stem Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Mode Of Action
        • 8.3.5.2.2. By Cancer Forms

9. Middle East & Africa Cancer Stem Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Mode Of Action
    • 9.2.2. By Cancer Forms
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cancer Stem Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Mode Of Action
        • 9.3.1.2.2. By Cancer Forms
    • 9.3.2. UAE Cancer Stem Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Mode Of Action
        • 9.3.2.2.2. By Cancer Forms
    • 9.3.3. South Africa Cancer Stem Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Mode Of Action
        • 9.3.3.2.2. By Cancer Forms

10. South America Cancer Stem Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Mode Of Action
    • 10.2.2. By Cancer Forms
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Stem Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Mode Of Action
        • 10.3.1.2.2. By Cancer Forms
    • 10.3.2. Colombia Cancer Stem Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Mode Of Action
        • 10.3.2.2.2. By Cancer Forms
    • 10.3.3. Argentina Cancer Stem Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Mode Of Action
        • 10.3.3.2.2. By Cancer Forms

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cancer Stem Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AbbVie, Inc.
  • 15.3. Lonza Group Ltd
  • 15.4. The Menarini Group
  • 15.5. Miltenyi Biotec B.V. & Co. KG
  • 15.6. PromoCell GmbH
  • 15.7. MacroGenics, Inc.
  • 15.8. STEMCELL Technologies Canada Inc.
  • 15.9. Sino Biological, Inc.
  • 15.10. Lineage Cell Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer